



ASX ANNOUNCEMENT
27 February 2015

Bionomics to Present at Upcoming March U.S. Conferences

Bionomics Limited (ASX:BNO, ADR:BMICY), a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of cancer and diseases of the central nervous system, today announced that Dr. Deborah Rathjen, CEO and Managing Director, will present a corporate overview at the following upcoming U.S. conferences in March:

- **Cowen & Co. 35th Annual Health Care Conference** on Tuesday, March 3, 2015 at 8:00 a.m. ET in Boston, MA.
- **ASX Spotlight New York 2015** on Thursday, March 5, 2015 at 11:35 a.m. ET in New York, NY.
- **27th Annual ROTH Conference** on Tuesday, March 10, 2015 at 5:30 p.m. PT in Dana Point, CA.

FOR FURTHER INFORMATION PLEASE CONTACT:

Bionomics Limited

Dr. Deborah Rathjen
CEO & Managing Director
+61 (0)8 8354 6101 /
0418 160 425
drathjen@bionomics.com.au

Monsoon Communications

Rudi Michelson
+61 (0)3 9620 3333
rudim@monsoon.com.au

Stern IR

Beth DelGiacco
+1 (212) 362 1200
Beth@sternir.com

About Bionomics Limited

Bionomics (ASX: BNO) is a biopharmaceutical company which discovers and develops innovative therapeutics for cancer and diseases of the central nervous system. Bionomics has small molecule product development programs in the areas of cancer, anxiety, memory loss and pain. Its oncology approach includes cancer stem cell therapeutics as well as vascular disruption in solid tumours.

Bionomics' discovery and development activities are driven by its four proprietary technology platforms: MultiCore®, a diversity orientated chemistry platform for the discovery of small molecule drugs; ionX®, a set of novel technologies for the identification of drugs targeting ion channels for diseases of the central nervous system; Angene®, a drug discovery platform which incorporates a variety of genomics tools to identify and validate novel angiogenesis targets (involved in the formation of new blood vessels); and CSC Rx Discovery™, which identifies antibody and small molecule therapeutics that inhibit the growth of cancer stem cells. These platforms drive Bionomics' pipeline and underpin its established business strategy of securing partners for its key compounds. Bionomics partners include Merck & Co.

www.bionomics.com.au